CDA | Evidence Driven
CDA | Evidence Driven

Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details

Details

Files
Generic Name:
Lorlatinib
Project Status:
Complete
Therapeutic Area:
Non-Small Cell Lung Cancer (NSCLC)
Manufacturer:
Pfizer Canada ULC
Brand Name:
Lorbrena
Project Line:
Reimbursement Review
Project Number:
PC0183-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Strength:
25 mg & 100 mg
Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer (NSCLC)
Funding Request:
For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on: crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or alectinib.
Sponsor:
Pfizer Canada ULC
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Lorlatinib (Lorbrena) NSCLC – pERC Final Recommendation Final Recommendation January 30, 2020 View PDF
Lorlatinib (Lorbrena) NSCLC – Final Economic Guidance Report Guidance Reports January 30, 2020 View PDF
Lorlatinib (Lorbrena) NSCLC – Final Clinical Guidance Report Guidance Reports January 30, 2020 View PDF
Lorlatinib (Lorbrena) NSCLC – pERC Initial Recommendation Initial Recommendation December 5, 2019 View PDF
Lorlatinib (Lorbrena) NSCLC – PAG Feedback on Initial Recommendation Feedback January 30, 2020 View PDF
Lorlatinib (Lorbrena) NSCLC – Manufacturer Feedback on Initial Recommendation Feedback January 30, 2020 View PDF
Lorlatinib (Lorbrena) NSCLC – Patient Advocacy Group Feedback on Initial Recommendation Feedback January 30, 2020 View PDF
Lorlatinib (Lorbrena) NSCLC – Clinician Feedback on Initial Recommendation Feedback January 30, 2020 View PDF
Lorlatinib (Lorbrena) NSCLC – Patient Advocacy Group COI Declarations COI Declarations January 30, 2020 View PDF
Lorlatinib (Lorbrena) NSCLC – Clinician COI Declarations COI Declarations January 30, 2020 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : February 14, 2020